{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-031141","form_type":"8-K","ticker":"RNLXY","cik":"0001811115","company_name":"Renalytix plc","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.630703+00:00","generated_at":"2026-06-04T21:29:08.355253+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"KidneyIntelX included in final KDIGO 2024 guideline for CKD risk prediction","bullets":["KidneyIntelX recommended for predicting CKD progression in stages G1-G3 per KDIGO 2024 guideline released March 13.","FDA de-novo marketing authorization for kidneyintelX.dkd received June 2023 for use in type 2 diabetes patients.","Outcomes data from >2,500 patients showed sustained reduction in eGFR decline and improved diabetes/cardiovascular management.","Current enrollment >9,000 patients with type 2 diabetes and CKD for ongoing clinical utility and outcomes studies.","Guideline emphasizes risk prediction and personalized treatment; Renalytix aims to expand evidence base."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-031141","json":"https://secwatch.observer/filing/0000950170-24-031141.json","markdown":"https://secwatch.observer/filing/0000950170-24-031141.md","text":"https://secwatch.observer/filing/0000950170-24-031141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024031141/0000950170-24-031141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024031141/rnlx-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T21:29:08.355253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}